Fill Out Your Profile to share more about you. Learn more...
Webinar: Corrective Breast Reconstruction: Getting the Results You Want Join us July 9, 2024 at 6pm ET. Register here.

FDA Approves Orserdu for ER+ MBC (oral SERD)


FDA Approves Orserdu for Metastatic, Estrogen Receptor-Positive Breast Cancer
Jan 27, 2023

The FDA has approved Orserdu, a new oral medicine to treat metastatic, estrogen receptor-positive, HER2-negative breast cancer with an ESR1 mutation. Read more....